{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:42:13Z","timestamp":1785796933740,"version":"3.56.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,5,8]],"date-time":"2014-05-08T00:00:00Z","timestamp":1399507200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s10067-014-2650-y","type":"journal-article","created":{"date-parts":[[2014,5,7]],"date-time":"2014-05-07T02:06:02Z","timestamp":1399428362000},"page":"1367-1375","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Glucocorticoid-resistant polymyalgia rheumatica: pretreatment characteristics and tocilizumab therapy"],"prefix":"10.1007","volume":"35","author":[{"given":"Shunsuke","family":"Mori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinori","family":"Koga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,5,8]]},"reference":[{"key":"2650_CR1","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/annrheumdis-2011-200329","volume":"71","author":"B Dasgupta","year":"2012","unstructured":"Dasgupta B, Cimmino MA, Maradit-Kremers H, Schmidt WA, Schirmer M, Salvarani C et al (2012) 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative. Ann Rheum Dis 71:484\u2013492","journal-title":"Ann Rheum Dis"},{"key":"2650_CR2","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/1529-0131(199807)41:7<1221::AID-ART12>3.0.CO;2-W","volume":"41","author":"C Salvarani","year":"1998","unstructured":"Salvarani C, Cantini F, Macchioni P, Olivieri I, Niccoli L, Padula A et al (1998) Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum 41:1221\u20131226","journal-title":"Arthritis Rheum"},{"key":"2650_CR3","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3109\/s10165-007-0595-6","volume":"17","author":"S Mori","year":"2007","unstructured":"Mori S, Koga Y, Ito K (2007) Clinical characteristics of polymyalgia rheumatica in Japanese patients: evidence of synovitis and extracapsular inflammatory changes by fat suppression magnetic resonance imaging. Mod Rheumatol 17:369\u2013375","journal-title":"Mod Rheumatol"},{"key":"2650_CR4","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/rheumatology\/kep303a","volume":"49","author":"B Dasgupta","year":"2010","unstructured":"Dasgupta B, Borg FA, Hassan N, Barraclough K, Bourke B, Fulcher J et al (2010) BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford) 49:186\u2013190","journal-title":"Rheumatology (Oxford)"},{"key":"2650_CR5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/art.20901","volume":"53","author":"C Salvarani","year":"2005","unstructured":"Salvarani C, Cantini F, Niccoli L, Macchioni P, Consonni D, Bajocchi G et al (2005) Acute-phase reactants and the risk of relapse\/recurrence in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum 53:33\u201338","journal-title":"Arthritis Rheum"},{"key":"2650_CR6","first-page":"65","volume":"32","author":"HM Kremers","year":"2005","unstructured":"Kremers HM, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE (2005) Relapse in a population based cohort of patients with polymyalgia rheumatica. J Rheumatol 32:65\u201373","journal-title":"J Rheumatol"},{"key":"2650_CR7","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/art.23924","volume":"59","author":"L Pulsatelli","year":"2008","unstructured":"Pulsatelli L, Boiardi L, Pignotti E, Dolzani P, Silvestri T, Macchioni P et al (2008) Serum interleukin-6 receptor in polymyalgia rheumatica: a potential marker of relapse\/recurrence risk. Arthritis Rheum 59:1147\u20131154","journal-title":"Arthritis Rheum"},{"key":"2650_CR8","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1002\/art.1780401022","volume":"40","author":"SE Gabriel","year":"1997","unstructured":"Gabriel SE, Sunku J, Salvarani C, O'Fallon WM, Hunder GG (1997) Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 40:1873\u20131878","journal-title":"Arthritis Rheum"},{"key":"2650_CR9","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/art.22777","volume":"57","author":"A Hutchings","year":"2007","unstructured":"Hutchings A, Hollywood J, Lamping DL, Pease CT, Chakravarty K, Silverman B et al (2007) Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. Arthritis Rheum 57:803\u2013809","journal-title":"Arthritis Rheum"},{"key":"2650_CR10","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1136\/ard.38.5.434","volume":"38","author":"HA Bird","year":"1979","unstructured":"Bird HA, Esselinckx W, Dixon AS, Mowat AG, Wood PH (1979) An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 38:434\u2013439","journal-title":"Ann Rheum Dis"},{"key":"2650_CR11","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1136\/ard.48.8.658","volume":"48","author":"V Kyle","year":"1989","unstructured":"Kyle V, Hazleman BL (1989) Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months. Ann Rheum Dis 48:658\u2013661","journal-title":"Ann Rheum Dis"},{"key":"2650_CR12","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1136\/ard.48.8.662","volume":"48","author":"V Kyle","year":"1989","unstructured":"Kyle V, Hazleman BL (1989) Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects. Ann Rheum Dis 48:662\u2013666","journal-title":"Ann Rheum Dis"},{"key":"2650_CR13","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/art.22771","volume":"57","author":"BF Leeb","year":"2007","unstructured":"Leeb BF, Rintelen B, Sautner J, Fassl C, Bird HA (2007) The polymyalgia rheumatica activity score in daily use: proposal for a definition of remission. Arthritis Rheum 57:810\u2013815","journal-title":"Arthritis Rheum"},{"key":"2650_CR14","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1136\/ard.2003.011379","volume":"63","author":"BF Leeb","year":"2004","unstructured":"Leeb BF, Bird HA (2004) A disease activity score for polymyalgia rheumatica. Ann Rheum Dis 63:1279\u20131283","journal-title":"Ann Rheum Dis"},{"key":"2650_CR15","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3899\/jrheum.091185","volume":"37","author":"K Hagihara","year":"2010","unstructured":"Hagihara K, Kawase I, Tanaka T, Kishimoto T (2010) Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica. J Rheumatol 37:1075\u20131076","journal-title":"J Rheumatol"},{"key":"2650_CR16","doi-asserted-by":"crossref","unstructured":"Christidis D, Jain S, Das Gupta B (2011) Successful use of tocilizumab in polymyalgic onset biopsy positive GCA with large vessel involvement. BMJ Case Rep","DOI":"10.1136\/bcr.04.2011.4135"},{"key":"2650_CR17","first-page":"w13156","volume":"141","author":"M Seitz","year":"2011","unstructured":"Seitz M, Reichenbach S, Bonel HM, Adler S, Wermelinger F, Villiger PM (2011) Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly 141:w13156","journal-title":"Swiss Med Wkly"},{"key":"2650_CR18","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1002\/acr.21750","volume":"64","author":"S Unizony","year":"2012","unstructured":"Unizony S, Arias-Urdaneta L, Miloslavsky E, Arvikar S, Khosroshahi A, Keroack B et al (2012) Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken) 64:1720\u20131729","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2650_CR19","doi-asserted-by":"crossref","unstructured":"Ashraf FA, Anjum S, Hussaini A, Fraser A (2013) Refractory PMR with aortitis: life-saving treatment with anti-IL6 monoclonal antibody (tocilizumab) and surgical reconstruction of the ascending aorta. BMJ Case Rep","DOI":"10.1136\/bcr-2013-009523"},{"key":"2650_CR20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.semarthrit.2013.01.003","volume":"43","author":"P Macchioni","year":"2013","unstructured":"Macchioni P, Boiardi L, Catanoso M, Pulsatelli L, Pipitone N, Meliconi R et al (2013) Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature. Semin Arthritis Rheum 43:113\u2013118","journal-title":"Semin Arthritis Rheum"},{"key":"2650_CR21","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/RHU.0b013e3182a6aa0e","volume":"19","author":"A Al Rashidi","year":"2013","unstructured":"Al Rashidi A, Hegazi MO, Mohammad SA, Varghese A (2013) Effective control of polymyalgia rheumatica with tocilizumab. J Clin Rheumatol 19:400\u2013401","journal-title":"J Clin Rheumatol"},{"key":"2650_CR22","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/rheumatology\/29.6.456","volume":"29","author":"B Dasgupta","year":"1990","unstructured":"Dasgupta B, Panayi GS (1990) Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol 29:456\u2013458","journal-title":"Br J Rheumatol"},{"key":"2650_CR23","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/art.1780360913","volume":"36","author":"NE Roche","year":"1993","unstructured":"Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM (1993) Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 36:1286\u20131294","journal-title":"Arthritis Rheum"},{"key":"2650_CR24","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1093\/rheumatology\/36.9.976","volume":"36","author":"VM Corrigall","year":"1997","unstructured":"Corrigall VM, Dolan AL, Dasgupta B, Panayi GS (1997) The sequential analysis of T lymphocyte subsets and interleukin-6 in polymyalgia rheumatica patients as predictors of disease remission and steroid withdrawal. Br J Rheumatol 36:976\u2013980","journal-title":"Br J Rheumatol"},{"key":"2650_CR25","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/rheumatology\/37.7.766","volume":"37","author":"A Uddhammar","year":"1998","unstructured":"Uddhammar A, Sundqvist KG, Ellis B, Rantapaa-Dahlqvist S (1998) Cytokines and adhesion molecules in patients with polymyalgia rheumatica. Br J Rheumatol 37:766\u2013769","journal-title":"Br J Rheumatol"},{"key":"2650_CR26","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/rheumatology\/39.6.624","volume":"39","author":"RH Straub","year":"2000","unstructured":"Straub RH, Gluck T, Cutolo M, Georgi J, Helmke K, Scholmerich J et al (2000) The adrenal steroid status in relation to inflammatory cytokines (interleukin-6 and tumour necrosis factor) in polymyalgia rheumatica. Rheumatology (Oxford) 39:624\u2013631","journal-title":"Rheumatology (Oxford)"},{"key":"2650_CR27","first-page":"748","volume":"29","author":"M Cutolo","year":"2002","unstructured":"Cutolo M, Straub RH, Foppiani L, Prete C, Pulsatelli L, Sulli A et al (2002) Adrenal gland hypofunction in active polymyalgia rheumatica. Effect of glucocorticoid treatment on adrenal hormones and interleukin 6. J Rheumatol 29:748\u2013756","journal-title":"J Rheumatol"},{"key":"2650_CR28","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/ard.2006.051979","volume":"65","author":"M Cutolo","year":"2006","unstructured":"Cutolo M, Montecucco CM, Cavagna L, Caporali R, Capellino S, Montagna P et al (2006) Serum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritis. Ann Rheum Dis 65:1438\u20131443","journal-title":"Ann Rheum Dis"},{"key":"2650_CR29","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/ard.2008.103663","volume":"69","author":"L Alvarez-Rodriguez","year":"2010","unstructured":"Alvarez-Rodriguez L, Lopez-Hoyos M, Mata C, Marin MJ, Calvo-Alen J, Blanco R et al (2010) Circulating cytokines in active polymyalgia rheumatica. Ann Rheum Dis 69:263\u2013269","journal-title":"Ann Rheum Dis"},{"key":"2650_CR30","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/ard.55.6.403-b","volume":"55","author":"D Caplanne","year":"1996","unstructured":"Caplanne D, Le Parc JM, Alexandre JA (1996) Interleukin-6 in clinical relapses of polymyalgia rheumatica and giant cell arteritis. Ann Rheum Dis 55:403\u2013404","journal-title":"Ann Rheum Dis"},{"key":"2650_CR31","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/archinte.159.6.577","volume":"159","author":"CM Weyand","year":"1999","unstructured":"Weyand CM, Fulbright JW, Evans JM, Hunder GG, Goronzy JJ (1999) Corticosteroid requirements in polymyalgia rheumatica. Arch Intern Med 159:577\u2013584","journal-title":"Arch Intern Med"},{"key":"2650_CR32","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cyto.2008.09.004","volume":"44","author":"VM Martinez-Taboada","year":"2008","unstructured":"Martinez-Taboada VM, Alvarez L, RuizSoto M, Marin-Vidalled MJ, Lopez-Hoyos M (2008) Giant cell arteritis and polymyalgia rheumatica: role of cytokines in the pathogenesis and implications for treatment. Cytokine 44:207\u2013220","journal-title":"Cytokine"},{"key":"2650_CR33","doi-asserted-by":"crossref","first-page":"493","DOI":"10.7326\/0003-4819-141-7-200410050-00005","volume":"141","author":"R Caporali","year":"2004","unstructured":"Caporali R, Cimmino MA, Ferraccioli G, Gerli R, Klersy C, Salvarani C et al (2004) Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 141:493\u2013500","journal-title":"Ann Intern Med"},{"key":"2650_CR34","first-page":"395","volume":"26","author":"MA Cimmino","year":"2008","unstructured":"Cimmino MA, Salvarani C, Macchioni P, Gerli R, Bartoloni Bocci E, Montecucco C et al (2008) Long-term follow-up of polymyalgia rheumatica patients treated with methotrexate and steroids. Clin Exp Rheumatol 26:395\u2013400","journal-title":"Clin Exp Rheumatol"},{"key":"2650_CR35","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1136\/ard.55.4.218","volume":"55","author":"MJ Veen van der","year":"1996","unstructured":"van der Veen MJ, Dinant HJ, van Booma-Frankfort C, van Albada-Kuipers GA, Bijlsma JW (1996) Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis 55:218\u2013223","journal-title":"Ann Rheum Dis"},{"key":"2650_CR36","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1196\/annals.1351.030","volume":"1069","author":"MA Cimmino","year":"2006","unstructured":"Cimmino MA, Parodi M, Caporali R, Montecucco C (2006) Is the course of steroid-treated polymyalgia rheumatica more severe in women? Ann N Y Acad Sci 1069:315\u2013321","journal-title":"Ann N Y Acad Sci"},{"key":"2650_CR37","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s00296-012-2580-4","volume":"33","author":"JH Lee","year":"2013","unstructured":"Lee JH, Choi ST, Kim JS, Yoon BY, Kwok SK, Kim HS et al (2013) Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR). Rheumatol Int 33:1475\u20131480","journal-title":"Rheumatol Int"},{"key":"2650_CR38","first-page":"1945","volume":"26","author":"J Narvaez","year":"1999","unstructured":"Narvaez J, Nolla-Sole JM, Clavaguera MT, Valverde-Garcia J, Roig-Escofet D (1999) Longterm therapy in polymyalgia rheumatica: effect of coexistent temporal arteritis. J Rheumatol 26:1945\u20131952","journal-title":"J Rheumatol"},{"key":"2650_CR39","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/BF02208345","volume":"14","author":"S Schreiber","year":"1995","unstructured":"Schreiber S, Buyse M (1995) The CRP initial response to treatment as prognostic factor in patients with polymyalgia rheumatica. Clin Rheumatol 14:315\u2013318","journal-title":"Clin Rheumatol"},{"key":"2650_CR40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/sarh.2000.8366","volume":"30","author":"F Cantini","year":"2000","unstructured":"Cantini F, Salvarani C, Olivieri I, Macchioni L, Ranzi A, Niccoli L et al (2000) Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum 30:17\u201324","journal-title":"Semin Arthritis Rheum"},{"key":"2650_CR41","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1136\/ard.42.4.374","volume":"42","author":"AR Behn","year":"1983","unstructured":"Behn AR, Perera T, Myles AB (1983) Polymyalgia rheumatica and corticosteroids: how much for how long? Ann Rheum Dis 42:374\u2013378","journal-title":"Ann Rheum Dis"},{"key":"2650_CR42","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/ard.52.12.847","volume":"52","author":"V Kyle","year":"1993","unstructured":"Kyle V, Hazleman BL (1993) The clinical and laboratory course of polymyalgia rheumatica\/giant cell arteritis after the first two months of treatment. Ann Rheum Dis 52:847\u2013850","journal-title":"Ann Rheum Dis"},{"key":"2650_CR43","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0002-9343(85)90309-2","volume":"79","author":"WT Ayoub","year":"1985","unstructured":"Ayoub WT, Franklin CM, Torretti D (1985) Polymyalgia rheumatica. Duration of therapy and long-term outcome. Am J Med 79:309\u2013315","journal-title":"Am J Med"},{"key":"2650_CR44","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1471-2474-12-94","volume":"12","author":"MA Cimmino","year":"2011","unstructured":"Cimmino MA, Parodi M, Montecucco C, Caporali R (2011) The correct prednisone starting dose in polymyalgia rheumatica is related to body weight but not to disease severity. BMC Musculoskelet Disord 12:94","journal-title":"BMC Musculoskelet Disord"},{"key":"2650_CR45","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1136\/ard.2002.002618","volume":"62","author":"BF Leeb","year":"2003","unstructured":"Leeb BF, Bird HA, Nesher G, Andel I, Hueber W, Logar D et al (2003) EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT). Ann Rheum Dis 62:1189\u20131194","journal-title":"Ann Rheum Dis"},{"key":"2650_CR46","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/art.23338","volume":"59","author":"A Binard","year":"2008","unstructured":"Binard A, de Bandt M, Berthelot JM, Saraux A, Inflammatory Joint Disease Working Group of the French Society for R (2008) Performance of the polymyalgia rheumatica activity score for diagnosing disease flares. Arthritis Rheum 59:263\u2013269","journal-title":"Arthritis Rheum"},{"key":"2650_CR47","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/art.22630","volume":"57","author":"A Binard","year":"2007","unstructured":"Binard A, De Bandt M, Berthelot JM, Saraux A, Inflammatory Joint Disease Working Group CRIotFSfR (2007) Usefulness of the disease activity scores for polymyalgia rheumatica for predicting glucocorticoid dose changes: a study of 243 scenarios. Arthritis Rheum 57:481\u2013486","journal-title":"Arthritis Rheum"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-014-2650-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-014-2650-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-014-2650-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T22:52:17Z","timestamp":1553640737000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-014-2650-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,8]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["2650"],"URL":"https:\/\/doi.org\/10.1007\/s10067-014-2650-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,8]]}}}